The Merger (Schedule of company’s consolidated statement of operations and unaudited proforma information) (Details) - USD ($)	8 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
General and administrative expenses		$ 7,966,000	$ 9,265,000
Sale of Slovenia (Note 6)			700,000
Net loss		(22,181,000)	$ (19,479,000)
AmpliPhi Biosciences Corporation [Member]
Business Acquisition [Line Items]
Research and development expenses	$ 1,321,000	583,000
General and administrative expenses	1,917,000	1,205,000
Sale of Slovenia (Note 6)	663,000
Net loss	$ 3,901,000	$ 1,788,000